Investigational drug · Phase 2
Vapendavir
Also called: VPV, Vapendaivr
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Rhinovirus Infection, COPD Exacerbation Acute, COPD With Acute Lower Respiratory Infection.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
9
Any phase or sponsor naming "Vapendavir"
First trial start
2023
Nov 20, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Vapendavir", any sponsor or status.
Conditions studied
As listed on its trial records.
- Rhinovirus Infection
- COPD Exacerbation Acute
- COPD With Acute Lower Respiratory Infection
- Rhinovirus
- Virus Diseases
- Virus Infection, RNA
- Enterovirus
- Enterovirus Infections
- Infection Viral
- Respiratory Complication
Approved drugs for the same conditions: COPD · Infectious disease and vaccines · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "Vapendavir" as an intervention, largest first.
- A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus InfectionPivotal-lookingCompleted
Biota Pharmaceuticals, Inc.Industry
NCT02367313 · 455 participants · Start Feb 2015 · Primary completion Dec 2016
Drug: Vapendavir; Vapendavir and 1 more · For: Asthma
Sites: Birmingham, Alabama; Flagstaff, Arizona; Bakersfield, California · 62 sites in all
- Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPDPivotal-lookingRecruiting
Altesa Biosciences, Inc.Industry
NCT07610395 · 180 participants (planned) · Start May 1, 2026 · Primary completion Nov 15, 2027
Drug: VPV 1000 mg; VPV 500 mg · For: Rhinovirus Infection
Sites: Mobile, Alabama; Tempe, Arizona; Inglewood, California · 46 sites in all
- RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory InfectionCompleted
Altesa Biosciences, Inc.Industry
NCT06149494 · 52 participants · Start Nov 20, 2023 · Primary completion Mar 30, 2025
Drug: Vapendavir; Placebo · For: COPD Exacerbation Acute; COPD With Acute Lower Respiratory Infection; Rhinovirus and 33 more
Sites: London, United Kingdom
Aviragen TherapeuticsIndustry
NCT02877264 · 48 participants · Start Jun 2016 · Primary completion Aug 2016
Drug: vapendavir 132 mg capsule; vapendavir 264 mg tablet and 1 more · For: Healthy
Sites: Saint Paul, Minnesota
Biota Pharmaceuticals, Inc.Industry
NCT02101866 · 36 participants · Start Mar 2014 · Primary completion May 2014
Drug: Vapendavir 300 mg tablet; Vapendavir 132 mg capsules · For: Healthy
Sites: Saint Paul, Minnesota
Biota Scientific Management Pty LtdIndustry
NCT02204501 · 24 participants · Start May 2014 · Primary completion Jun 2014
Drug: Midazolam 5mg Syrup; Vapendavir 264 mg BID and 1 more · For: Drug-Drug Interaction Healthy Volunteers
Sites: Saint Paul, Minnesota
Altesa Biosciences, Inc.Industry
NCT05962645 · 21 participants · Start May 19, 2023 · Primary completion Dec 12, 2023
Drug: Vapendavir · For: COPD; Respiratory Disease; Lower Respiratory Disease and 2 more
Sites: Miami, Florida
Altesa Biosciences, Inc.Industry
NCT06834295 · 8 participants · Start Mar 12, 2025 · Primary completion Mar 23, 2025
Drug: Vapendavir · For: Healthy Males
Sites: Nottingham, United Kingdom
VaxartIndustry
NCT03024177 · 0 participants · Primary completion Apr 2017
Drug: Vapendavir; Placebo Oral Tablet · For: Rhinovirus; Upper Respiratory Tract Infection
Newest research
PubMed records naming it or its code names, newest first.
- Short-term Outcomes of Fat Injection for Posterior Pharyngeal Wall Augmentation in the Management of Velopharyngeal Insufficiency with Different Etiologies.
Salem MA, El-Sherbeny WA, Baz H, et al. · ORL J Otorhinolaryngol Relat Spec 2026
- Post-cardiotomy ECMO configurations after mitral valve replacement: a case series and strategy development.
Giunta M, Loforte A, Orsello A, et al. · Perfusion 2026
- Association between post-adenoidectomy hypernasality and velopharyngeal valve closure patterns.
Yasien DG, Alariney RK, ElSheikh M, et al. · Eur Arch Otorhinolaryngol 2025
- Impact of visual preferences for indoor green walls on emotion and brain activity of college students.
Wang M, Zhang N, Yang L, et al. · Sci Rep 2025
- The Relation of Skeletal Malocclusion and Airway Volumes: A Cross-Sectional Study.
SohrabiFar A, Maleki D, Maleki A, et al. · Int J Dent 2025
- Structure-Activity Relationship Studies Towards Analogues of Pleconaril as Novel Enterovirus-D68 Capsid-Targeting Antivirals.
Cousins DL, Griffen EJ, Stacey J, et al. · bioRxiv 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.